Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Trading Update

8 Feb 2012 07:00

CERES MEDIA INTERNATIONAL PLC ("Ceres", "the Company" or "the Group") Trading update

Further to the announcement made 19 December 2011, the Company has now resolved the technical issues associated with the production of its TierraFilm range and has taken delivery of stock of this product and, upon receipt of an order, can be immediately delivered. The TierraFilm products are currently being trialled by distributors, printers and end users and the feedback received by the Company from the trials has been positive.

TierraFilm products are designed as an environmental alternative to the coated paper or oil based materials typically used in the print industry. They are manufactured using Sustainable Forestry InitiativeTM (SFI) certified raw materials and can be disposed of in existing biodegradation, composting or Energy From Waste systems removing the need to landfill.

Delays in scaling up production and bringing TierraFilm to the market together with the slower than anticipated take-up of Gossyp and Chorus products, as previously announced, have had a consequential impact on the Company's working capital position, which the board is monitoring closely. The board has also taken action to reduce the cost base of the Company in order to conserve its cash position.

The sales of Chorus and Gossyp, the Company's other principal products, continue to be significantly below the board's expectations and the Company is continuing to refocus its sales strategy in relation to these products.

A further update will be made in due course.

For further information, please contact:

Ceres Media International PLC Tel: 020 3178 5622 Alex Dowdeswell Leslie Barber Nominated Adviser Tel: 020 7148 7900 Cairn Financial Advisers LLP Jo Turner / Liam Murray Broker Tel: 020 3002 2070 First Columbus LLP

Chris Crawford / Kelly Gardiner Financial PR Tel: 020 7556 1063 De Facto Financial

Mike Wort / Anna Dunphy

XLON
Date   Source Headline
24th Aug 20229:05 amRNSSecond Price Monitoring Extn
24th Aug 20229:00 amRNSPrice Monitoring Extension
24th Aug 20227:00 amRNSTrading update
26th Jul 202212:31 pmRNSResult of AGM
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.